Pharvaris (NASDAQ:PHVS) Stock Price Down 8.4% – What’s Next?

Pharvaris (NASDAQ:PHVS) shares traded down 8.4% during trading on Monday . The stock traded as low as $13.13 and last traded at $13.08. 4,997 shares traded hands during trading, a decline of 93% from the average session volume of 71,812 shares. The stock had previously closed at $14.28.

Analyst Upgrades and Downgrades

Separately, JMP Securities lifted their target price on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research report on Friday, January 31st.

Pharvaris Price Performance

The firm has a market capitalization of $643.17 million, a price-to-earnings ratio of -4.39 and a beta of -2.84. The firm has a 50 day moving average price of $15.76 and a 200-day moving average price of $18.46.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.06. Equities research analysts predict that Pharvaris will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Soleus Capital Management L.P. lifted its position in shares of Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock worth $15,617,000 after purchasing an additional 216,483 shares during the last quarter. FMR LLC raised its stake in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company’s stock valued at $103,429,000 after buying an additional 189,714 shares in the last quarter. Octagon Capital Advisors LP lifted its holdings in Pharvaris by 25.4% during the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock worth $14,914,000 after buying an additional 157,530 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after acquiring an additional 118,408 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Pharvaris by 483.9% in the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company’s stock valued at $1,762,000 after acquiring an additional 76,188 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.